InsiderTrades

Form 4 for AMLX Amylyx Pharmaceuticals, Inc.

Accepted 2026-01-20 00:00:00 ET · period of report 2026-01-15 · accession 0001193125-26-017056 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2026-01-20 2026-01-15+ AMLX Klee Justin B. Co-CEO, Dir M - OptEx $7.57 +200.0K 3.38M +6% +$1.51M
DM 2026-01-20 2026-01-15+ AMLX Klee Justin B. Co-CEO, Dir S - Sale+OE $13.58 -138.2K 3.38M -4% -$1.88M
DM 2026-01-20 2026-01-15+ AMLX Klee Justin B. Co-CEO, Dir M - OptEx $0.00 -200.0K 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-01-15 M A 197,153 $7.57 3,514,739 D — —
2 Common Common Stock 2026-01-15 S D 136,193 $13.58 3,378,546 D — — (F2) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.26 to $13.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
3 Common Common Stock 2026-01-16 M A 2,847 $7.57 3,381,393 D — —
4 Common Common Stock 2026-01-16 S D 1,995 $13.89 3,379,398 D — — (F3) The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $13.83 to $13.91. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
5 Derivative Stock Option (Right to Buy) 2026-01-15 M D 197,153 $0.00 2,847 D $7.57 · — to 2026-02-19 197,153 Common Stock (F4) This option is fully vested and exercisable. The option is due to expire on February 19, 2026.
6 Derivative Stock Option (Right to Buy) 2026-01-16 M D 2,847 $0.00 0 D $7.57 · — to 2026-02-19 2,847 Common Stock (F4) This option is fully vested and exercisable. The option is due to expire on February 19, 2026.